FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2584792929> ?p ?o ?g. }

• W2584792929 abstract "Abstract Abstract 3385 Poster Board III-273 Allogeneic hematopoietic cell transplantation (HCT) for chronic lymphocytic leukemia (CLL) is increasingly utilized. We retrospectively analyzed outcomes of HCT for 43 patients with CLL at the University of Minnesota from February 1985 through March 2009 using myeloablative (MA, n=19) (total body irradiation [TBI] 1320 cGY in 8 fractions and cyclophosphamide [Cy] 60 mg/kg x 2 days) and non-myeloablative (NMA, n=24) preparative regimens (fludarabine 40 mg/m2 × 5 days or cladribine 50 mg/m2 IV with TBI 200cGy in 1 fraction and either oral busulfan [Bu] 8 mg/kg divided every 6 hours over 2 days or Cy 50 mg/kg x1 day). Graft-versus-host disease (GVHD) prophylaxis included cyclosporine (CSA) and methotrexate in most MA patients and CSA and mycophenolate mofetil (MMF) for all NMA patients. Median follow up for survivors was 3.3 years. Nine-two percent of NMA HCT took place after 2000 whereas only 26% of MA HCTs happened during this time. Most patients were male (15/19 MA, 20/24 NMA). Time from diagnosis to treatment was nearly twice as long in NMA vs. MA patients (median 72 vs. 39 months) with MA patients progressing through a median of 3 regimens (range, 1-5) and NMA 4 (1-7). Poor-risk cytogenetics (11q-, 17p-) were found in 5 MA and 10 NMA patients. Seven and 13 patients were fludarabine refractory in the MA and NMA groups, respectively. Eighteen patients in the MA group had matched related donors (MRD), while only 10 MRD were amongst the NMA patients. Umbilical cord blood stem cells were used in 12 NMA patients. Neutrophil recovery was slightly faster after NMA HCT vs. MA (median 12.5 vs. 18.5 days; p=0.14). Incidence of acute GVHD, grades II-IV, was similar (p=0.11) but grades III-IV at day 100 was more frequent in the NMA than the MA group (33% vs. 5%, p=0.04). The chronic GVHD incidence was 43% (95% CI, 18-68%) in MA and 29% in NMA (11-47%, p=0.08) patients. Transplant-related mortality (TRM) at 1 year was 42% (20-64) in the MA arm vs. 25% (8-42) (p=0.34) for the NMA group. Relapse rates at 3 years were higher in the NMA HCT group (MA 18% [0-36] vs. NMA 26% [8-44]). Three-year progression-free survival (PFS) was similar in MA (33% [13-55]) and NMA (39% [19-58]) patients (p=0.61). Overall survival at three years was also similar (MA 37%, [15-60] vs. NMA 52%, [30-70]) (p=0.28). While these data suggest that dose intensity may affect TRM and relapse, NMA HCT yields equivalent and encouraging PFS and OS as compared to MA HCT. Our results support further investigation of the role of allogeneic transplantation in the treatment of high risk and advanced CLL. Disclosures: No relevant conflicts of interest to declare." @default.
• W2584792929 created "2017-02-10" @default.
• W2584792929 creator A5031800440 @default.
• W2584792929 creator A5040328429 @default.
• W2584792929 creator A5060449393 @default.
• W2584792929 creator A5067489954 @default.
• W2584792929 creator A5070132319 @default.
• W2584792929 creator A5080104357 @default.
• W2584792929 creator A5084230861 @default.
• W2584792929 date "2009-11-20" @default.
• W2584792929 modified "2023-09-27" @default.
• W2584792929 title "Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia: Similar Efficacy of Non-Myeloablative and Myeloablative Conditioning; Long-Term Evaluation From the University of Minnesota." @default.
• W2584792929 doi "https://doi.org/10.1182/blood.v114.22.3385.3385" @default.
• W2584792929 hasPublicationYear "2009" @default.
• W2584792929 type Work @default.
• W2584792929 sameAs 2584792929 @default.
• W2584792929 citedByCount "0" @default.
• W2584792929 crossrefType "journal-article" @default.
• W2584792929 hasAuthorship W2584792929A5031800440 @default.
• W2584792929 hasAuthorship W2584792929A5040328429 @default.
• W2584792929 hasAuthorship W2584792929A5060449393 @default.
• W2584792929 hasAuthorship W2584792929A5067489954 @default.
• W2584792929 hasAuthorship W2584792929A5070132319 @default.
• W2584792929 hasAuthorship W2584792929A5080104357 @default.
• W2584792929 hasAuthorship W2584792929A5084230861 @default.
• W2584792929 hasConcept C126322002 @default.
• W2584792929 hasConcept C141071460 @default.
• W2584792929 hasConcept C2776694085 @default.
• W2584792929 hasConcept C2776755627 @default.
• W2584792929 hasConcept C2777408962 @default.
• W2584792929 hasConcept C2777938653 @default.
• W2584792929 hasConcept C2778461978 @default.
• W2584792929 hasConcept C2778880498 @default.
• W2584792929 hasConcept C2779263901 @default.
• W2584792929 hasConcept C2779972918 @default.
• W2584792929 hasConcept C2780611847 @default.
• W2584792929 hasConcept C2911091166 @default.
• W2584792929 hasConcept C71924100 @default.
• W2584792929 hasConcept C90924648 @default.
• W2584792929 hasConceptScore W2584792929C126322002 @default.
• W2584792929 hasConceptScore W2584792929C141071460 @default.
• W2584792929 hasConceptScore W2584792929C2776694085 @default.
• W2584792929 hasConceptScore W2584792929C2776755627 @default.
• W2584792929 hasConceptScore W2584792929C2777408962 @default.
• W2584792929 hasConceptScore W2584792929C2777938653 @default.
• W2584792929 hasConceptScore W2584792929C2778461978 @default.
• W2584792929 hasConceptScore W2584792929C2778880498 @default.
• W2584792929 hasConceptScore W2584792929C2779263901 @default.
• W2584792929 hasConceptScore W2584792929C2779972918 @default.
• W2584792929 hasConceptScore W2584792929C2780611847 @default.
• W2584792929 hasConceptScore W2584792929C2911091166 @default.
• W2584792929 hasConceptScore W2584792929C71924100 @default.
• W2584792929 hasConceptScore W2584792929C90924648 @default.
• W2584792929 hasLocation W25847929291 @default.
• W2584792929 hasOpenAccess W2584792929 @default.
• W2584792929 hasPrimaryLocation W25847929291 @default.
• W2584792929 hasRelatedWork W1985868646 @default.
• W2584792929 hasRelatedWork W2297122519 @default.
• W2584792929 hasRelatedWork W2483286320 @default.
• W2584792929 hasRelatedWork W2492440520 @default.
• W2584792929 hasRelatedWork W2551420153 @default.
• W2584792929 hasRelatedWork W2557214410 @default.
• W2584792929 hasRelatedWork W2559062232 @default.
• W2584792929 hasRelatedWork W2560435871 @default.
• W2584792929 hasRelatedWork W2561213299 @default.
• W2584792929 hasRelatedWork W2564171273 @default.
• W2584792929 hasRelatedWork W2575554787 @default.
• W2584792929 hasRelatedWork W2576052929 @default.
• W2584792929 hasRelatedWork W2590899904 @default.
• W2584792929 hasRelatedWork W2592606920 @default.
• W2584792929 hasRelatedWork W2594121809 @default.
• W2584792929 hasRelatedWork W2595283582 @default.
• W2584792929 hasRelatedWork W2979545564 @default.
• W2584792929 hasRelatedWork W2985101498 @default.
• W2584792929 hasRelatedWork W3001533543 @default.
• W2584792929 hasRelatedWork W3097079471 @default.
• W2584792929 isParatext "false" @default.
• W2584792929 isRetracted "false" @default.
• W2584792929 magId "2584792929" @default.
• W2584792929 workType "article" @default.